Munich’s 3D Brain Model Poised to Revolutionize Alzheimer’s Research
Munich, Bavaria, Germany, August 16, 2026 – Scientists at the Ludwig Maximilian University of Munich (LMU) have successfully developed a novel 3D tissue model derived from human brain cells. This innovative model, which mimics the characteristic changes seen in Alzheimer’s disease, is expected to significantly advance research into the condition and aid in the discovery of new therapeutic agents. The findings, the culmination of nine years of development, were published in the prestigious journal Nature Neuroscience.
Focus on Cellular Interaction, Not Structure
The LMU research team emphasizes that for Alzheimer’s research, the interplay of various cell types and their functions is paramount, rather than a precise replication of the brain’s overall structure. The developed ‘mini-brains,’ roughly half the size of a pinhead, facilitate the interaction of three key brain cell types crucial to Alzheimer’s dementia.
Three Cell Types Form a Comprehensive Tissue Model
The researchers successfully stimulated human stem cells to differentiate into neurons, astrocytes, and microglial cells. Neurons form intricate networks and communicate with each other, while astrocytes provide them with nutrients and support their functions. Microglial cells, the brain’s immune cells, are responsible for clearing away dead cells and harmful substances. Neurobiologist and project leader Dominik Paquet explained that in a special nutrient solution, “these tissue spheres develop within a week, organizing themselves and taking on central brain functions.”
Accelerating Disease Processes Through Mutations
In this advanced tissue model, the three cell types can interact, and the genes and proteins vital for Alzheimer’s research are active, Paquet noted. The team also managed to induce Alzheimer’s-typical processes within the model, leading to cellular changes characteristic of the disease. Biochemist Christian Haass, an LMU researcher with decades of experience in Alzheimer’s research, explained that this was achieved through genetic engineering methods: “To prevent it from taking decades, as it does in humans, several mutations were introduced simultaneously. When combined, the effect is amplified.”
Microglia: A New Focus in Research
Similar to the human brain, the neurons in the tissue model exhibit typical plaques, which are protein deposits known as beta-amyloids. For a long time, these were believed to be solely responsible for the disease’s symptoms. However, recent findings indicate that other factors significantly increase the risk of developing Alzheimer’s in old age, as Christian Haass pointed out: “The genes for these risk factors were exclusively activated in the brain’s immune cells, the microglia.” This leads to a situation where these immune cells no longer protect neurons and fail to remove beta-amyloid deposits.
Amyloid and Tau: Unraveling the Mystery
Haass further noted that there is also a “communication” between amyloid deposits and another protein, the tau protein. This protein normally stabilizes neurons. However, amyloid plaques alter it, causing it to clump and damage nerve cells. “We have no idea how this works in detail,” Christian Haass admitted, stating, “Understanding this connection between amyloid and tau is the Holy Grail of Alzheimer’s research.” This understanding is also crucial for developing potentially effective medications against the disease.
Current Medications Offer Limited Efficacy
Currently, two antibody-based drugs, Lecanemab and Donanemab, have been approved in the EU for certain individuals in the early stages of Alzheimer’s disease. These drugs target amyloid deposits and “work quite well,” according to Christian Haass. However, their effectiveness is limited to patients who have not yet developed tau protein clumps. There is an urgent need for medications for patients with more advanced disease stages where tau clumping has already occurred. The new model will enable the testing of compounds that target clumped tau, amyloid, and support immune cell function.
Model Awaits Validation in Drug Testing
Dominik Paquet believes that the failure of many previously developed drugs to halt or cure the disease earlier stems from their testing on mice, whose neurons are not as susceptible to the disease. “And that’s where our model comes into play. This is a human model with human nerve cells.” While the model still requires improvements and cannot immediately be used for drug testing, Paquet sees a significant opportunity to develop Alzheimer’s medications that will be more effective in patients. The researchers are currently seeking a pharmaceutical industry partner interested in utilizing this tissue model.
This development marks a crucial step forward in the global fight against Alzheimer’s disease, offering new avenues for understanding its complex mechanisms and ultimately, finding a cure.
Source: https://www.br.de/nachrichten/wissen/muenchner-3d-hirn-modell-soll-alzheimer-forschung-voranbringen,VSBLbIi
